Externally controlled triggered-release of drug from PLGA micro and nanoparticles

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Hua, Xin ^a   Tan, Shengnan ^b   Bandara, H M H N ^c   Fu, Yujie ^b   Liu, Siguo ^a   Smyth, Hugh D C ^c  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NORTHEAST FORESTRY UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MAGNETIC NANOPARTICLE; NANOPARTICLE; POLYGLACTIN; DELAYED RELEASE FORMULATION; LACTIC ACID; MAGNETITE NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOFILM; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; IN VITRO STUDY; MAGNETIC FIELD; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HUMAN; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS INFECTIONS;

PSEUDOMONAS AERUGINOSA;

BIOFILMS; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; MAGNETITE NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84917705656     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114271     Document Type: Article

References (46)

1. Pierce GE (2005) Pseudomonas aeruginosa: Candida albicans: And device-related nosocomial infections: implications: Trends: And potential approaches for control. J. Ind. Microbiol. Biotechnol 32: 309-318.
2. Driscoll JA, Brody SL, Kollef MH (2007) The epidemiology: pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67: 351-368.
3. Wood DM, Smyth AR (2006) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane. Database. Syst Rev 1: CD004197.
4. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C (2007) NanoCipro Encapsulation in Monodisperse Large Porous PLGA Microparticles. J Contr Release 121: 100-109.
5. Ma Z, Ma L, Gao C, Shen J (2005) Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride. J Contr Release 104: 193-202.
6. Page Clisson ME, PintoAlphandary H, Ourevitch M, Andremont A, Couvreur P (1998) Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J Contr Release 56: 23-32.
7. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, et al. (2008) Biofilm penetration: Triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 61: 859-868.
8. Park TG (1995) Degradation of poly(lactide-co-glicolide acid) microspheres: effect of copolymer composition. Biomaterials 16: 1123-1130.
9. Vert M, Schwach G, Engel R, Coudane J (1998) Something new in the field of PLA/GA bioresorbable polymers: J Contr Release 53: 85-92.
10. Jain RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-coglicolide) (PLGA) devices. Biomaterials 21: 2475-2490.
11. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2000) Biodegradable polymeric nanoparticles as drug delivery devices. J Contr Release 70: 1-20.
12. Sahoo SK, Panyam J, Prabha S, Labhasetwar V (2002) Residual polyvinyl alcohol associated with poly(d:l-lactide-co-glicolide) nanoparticles affects their physical properties and cellular uptake. J Contr Release 82: 105-114.
13. Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Sol State Mater Sci 6: 319-327.
14. Ramchandani M, Robinson D (1998) In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Contr Release 54: 167-175.
15. Matthew MA, Gorman EM, Loren JS, Eric JM, Cory B (2007) NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Contr Release 121: 100-109.
16. Gorner T, Gref R, Michenot D, Sommer F, Tran MN, et al. (1999) Lidocaine-loaded biodegradable nanospheres. I. Optimization Of the drug incorporation into the polymer matrix. J Contr Release 57: 259- 268.
17. Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, et al. (2007) Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 96: 1282-1301.
18. Kimberly AK, Jason RM, Eric YS and Ralph W (2007) Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine 2: 153-167.
19. Peng XH, Qian XM, Mao H, Wang AY, Chen Z, et al. (2008) Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed 3: 311-321.
20. Subramani K, Hosseinkhani H, Khraisat A, Hosseinkhani M, Pathak Y (2009) Targeting nanoparticles as drug delivery systems for cancer treatment. Curr Nanosci 5: 135-140.
21. Hilger I, Fruhauf K, Andra W, Hiergeist R, Hergt R, et al. (2002) Heating potential of iron oxides for therapeutic purposes in interventional radiology Acad: Radiol 9: 198-202.
22. Rudolf H, Silvio D, Robert M, Matthias Z (2006) Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys Condens Matter 18: 2919-2934.
23. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C, et al. (2002) Magnetic drug targeting: biodistribution and dependency om magnetic field strength Magn Magn Mater 252: 363-366.
24. Fernandez-Pacheco R, Marquina C, Valdivia JG, Gutierrez M, Romero MS, et al. (2007) Magnetic nanoparticles for local drug delivery using magnetic implants. In: 6th international conference on the scientific and clinical applications of magnetic carriers. Elsevier Science BV 311: 318-322.
25. Roca AG, Wiese B, Timmis J, Vallejo-Fernandez G, O'Grady K (2012) Effect of Frequency and Field Amplitude in Magnetic Hyperthermia. IEEE T Magn 48: 4054-4057.
26. McGill SL, Cuylear CL, Adolphi NL, Osiński M, Smyth HD (2009) Magnetically Responsive Nanoparticles for Drug Delivery Applications Using Low Magnetic Field Strengths. IEEE T Nanobiosci 8: 33-42.
27. Pradhan P, Giri J, Rieken F, Koch C, Mykhaylyk O, et al. (2010) Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 142: 108-121.
28. Hu SH, Chen YY, Liu TC, Tung TH, Liu DM, et al. (2011) Remotely nano-rupturable yolk/shell capsules for magnetically-triggered drug release. Chem Commun 47: 1776-1778.
29. Shen JM, Yin T, Tian XZ, Gao FY, Xu S (2013) Surface Charge-Switchable Polymeric Magnetic Nanoparticles for the controlled release of anticancer drug. ACS Appl Mater Inter. 5: 7014-7024.
30. Kini S, Bahadur D, Panda D (2011) Magnetic PLGA Nanospheres: A Dual Therapy for Cancer. IEEE T Magn 47: 2882-2886.
31. Chiang WL, Ke CJ Z, Liao ZX, Chen SY, Chen FR, et al. (2012) Pulsatile Drug Release from PLGA Hollow Microspheres by Controlling the Permeability of Their Walls with a Magnetic Field. Small 8: 3584- 3588.
32. Bandara HMHN, Yau JYY, Watt RM, Jin LJ, Samaranayake LP (2010) Pseudomonas aeruginosa inhibits in-vitro Candida biofilm development. BMC Microbiol 10: 125.
33. Jin Y, Samaranayake LP, Samaranayake Y, Yip HK (2004) Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol 49: 789-798.
34. Jeong YI, Song JG, Kang SS, Ryu HH, Lee YH, et al. (2003) Preparation of poly(dl-lactide-coglycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm 259: 79-91.
35. Lee SC, Oh JT, Jang MH (1999) Chung SI Quantitative analysis of polyvinyl alcohol on the surface of poly(D: L-lactide-co-glycolide) microparticles pre-pared by solvent evaporation method: Effect of particle size and PVA concentration. J Contr Release 59: 123-132.
36. Cirpanli Y, Unlu N, Calis S, Hincal (2005) AA Formulation and in-vitro characterization of reti-noic acid loaded poly (lactic-co-glycolic acid) micro-spheres. J Microencapsul 22: 877-889.
37. Mahmoudi M, Simchi A, Imani M (2009) Cytotoxicity of Uncoated and Polyvinyl Alcohol Coated Superparamagnetic Iron Oxide Nanoparticles. J Phys Chem C 113: 9573-9580.
38. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H (2005) Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26: 2685-2694.
39. Jeremy SB, Saltzman WM (2008) High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Contr Release 129: 66-72.
40. Araujo J, Vega E, Lopes C, Egea MA, Garcia ML, et al. (2009) Effect of polymerviscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B 72: 48-56.
41. Yin J, Noda Y, Yotsuyanagi T (2006) Properties of poly(lactic-co-glycolic acid) nanospeheres containing protease inhibitors: Camostat mesilate and nafamostat mesilate. Int J Pharm 314: 46-55.
42. Hirenkumar KM, Steven JS (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 3: 1377-1397.
43. Ritger PL, Peppas NA (1987) A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. Journal of Controlled Release 5: 37-42.
44. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284: 1318-1322.
45. Xu C, Yuan Z, Kohler N, Kim J, Chung MA, et al. (2009) FePt Nanoparticles as an Fe Reservoir for Controlled Fe Release and Tumor Inhibition. J Am Chem Soc 131: 15346-15351.
46. Banin E, Vasil ML, Greenberg EP (2005) Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci 102: 11076-81.